Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ThermoGen Inc.

Division of Amgen Inc.

Latest From ThermoGen Inc.

Albany Molecular's Next Act

In the fast-growing chemistry services market, Albany Molecular has proven itself a steady and, in recent times, superlative performer. Albany Molecular is capitalizing on its growing revenue stream and strong market performance by building up chemistry capabilities to provide one-stop, albeit specialty, shopping. But the company's growth and above-average margins stem largely from its one major royalty deal, on Allegra--and the company has been spending its time on services, not on at-risk deals.Recent acquisitions position Albany Molecular to provide more proprietary technologies: the key is whether the company's management is willing to take the financial risk of deals in which it has to fund its own early development in order to win an important piece of a product's upside and thus boost it service-company margins.
BioPharmaceutical Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register